<DOC>
	<DOCNO>NCT01787474</DOCNO>
	<brief_summary>The goal clinical research study learn safety effect give special kind immune cell , call natural killer ( NK ) cell , high dose chemotherapy AML patient . Researchers want learn maximum tolerable number NK cell give . These NK cell may react leukemia cell , particularly mismatch certain HLA tissue type protein . In addition NK cell , receive cytarabine fludarabine try kill cancer cell prevent rejection NK cell .</brief_summary>
	<brief_title>IL-21-Expanded NK Cells Induction Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>While grow NK cell blood lab , mismatch T cell may also grow , cause reaction normal tissue call graft-vs-host disease ( GvHD ) . In lab , T cell remove cell product use special magnet antibody-coated magnetic bead . The drug aldesleukin ( interleukin-2 ) add NK cell improve function . The aldesleukin wash cell product give . The NK cell donate family member certain genetic type blood call HLA partly match . If agree take part study , assign dose level NK cell base join study . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue 86 dose level high tolerable dose NK cell find . One ( 1 ) 10 participant treat dose level . The day receive first NK cell infusion call Day 0 . The day receive NK cell infusion call minus day ( D- ) . The day receive NK cell infusion call plus day ( D+ ) . Study Drug Administration : On Day -7 , admit hospital give fluid vein hydrate . On Days -6 , -5 , -4 , -3 , -2 , receive fludarabine vein 30 minute . About 4 hour later , receive cytarabine vein 1 hour . If 60 year old old , `` rest '' ( receive chemotherapy ) Day -2 . On Day -1 , rest . Three ( 3 ) time week 2 week , receive NK cell vein 30 minute . You give standard drug help decrease risk side effect . You may ask study staff information drug give risk . You receive filgrastim injection skin 1 time day , start Day -7 continue white blood cell level high enough . Filgrastim design help growth white blood cell . Study Visits : Before treatment start : - Your medical history record . - You physical exam , include measurement vital sign ( blood pressure , heart rate , temperature , breathe rate ) . - Blood ( 2 teaspoon ) draw routine test . Before NK cell infusion : - Your medical history record . - You physical exam , include measurement vital sign . - Blood ( 2 teaspoon ) draw routine test . - The amount oxygen blood measure place sensor tip finger . Twice week , blood count low , blood ( 2 teaspoon ) draw routine test . Once blood count high enough , blood ( 2 teaspoon ) draw routine test week Day +56 . Once blood count high enough around Day +28 ( whichever earlier ) , bone marrow aspiration biopsy check status disease DNA test check cell bone marrow NK cell donor 's . To collect bone marrow aspiration/biopsy , area hip site numb anesthetic , small amount bone marrow bone withdrawn large needle . Blood ( 2 teaspoon ) draw test genetic makeup function infuse NK cell check status disease : - Before treatment start . - Before 1-3 hour NK cell infusion . - Once day Days +14 , +16 , +18 , +21 , weekly Day +56 . Length Study : Your participation study Day +56 . You take study early disease get bad , intolerable side effect occur , enough NK cell collect , unable follow study direction . This investigational study . Cytarabine , fludarabine , filgrastim FDA approve commercially available treatment AML . The investigational part study find best dose NK cell give goal help prevent cancer come back . The way researcher process NK cell investigational FDA approve . Up 30 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Patients relapse primary refractory AML . Patients relapse AML allogeneic stem cell transplantation , include receive donor lymphocyte infusion , eligible active GvHD immunosuppression . 2 . Have haploidentical family peripheral blood donor select best possible KIR reactivity . 3 . Patient age &gt; /= 18 year old . 4 . Performance status : Karnofsky Lansky Performance Scale ( PS ) great equal 70 . 5 . Renal function : Serum creatinine &lt; /=2 mg/dl creatinine clearance great equal 40 cc/min . Creatinine pediatric patient &lt; /=2 mg/dl &lt; /=2 time upper limit normal age ( whichever less ) . 6 . Pulmonary function : FEV1 , FVC DLCO &gt; /=50 % expect , correct hemoglobin . For pediatric patient , unable perform pulmonary function test ( child &lt; 7 year age ) , pulse oximetry &gt; /= 92 % room air pulse oximetry . 7 . Liver function : Total bilirubin &lt; /= 2 mg/dl &lt; /= 2.5 x ULN age ( unless Gilbert 's syndrome ) SGPT ( ALT ) &lt; /= 2.5 x ULN age . 8 . Cardiac function : leave ventricular ejection fraction &gt; /= 40 % . No uncontrolled arrhythmia uncontrolled symptomatic cardiac disease . 9 . Negative serum test rule pregnancy within 2 week prior registration female childbearing potential ( non childbearing potential define premenarchal , great one year postmenopausal , surgically sterilize ) . 10 . Sexually active male female childbearing potential must agree use form contraception consider effective medically acceptable Investigator . 11 . Negative serology human immunodeficiency virus ( HIV ) . 12 . Donor Eligibility Criteria Evaluation Prior Donation : Donor must 16 year age old weigh least 110 pound . 13 . Donor must HLAhaploidentical relative select best NK alloreactivity , define KIR gene present Donor NK cell relevant HLA haplotype ( KIR ligand ) absent Recipient present Donor select basis activate KIR gene content . 14 . Donor must meet standard institutional eligibility donor certification criterion therapeutic cell product donation . 15 . Not pregnant define negative serum ( beta HCG ) pregnancy test female childbearing potential ( Nonchildbearing potential define premenarchal , previous surgical sterilization , postmenopausal &gt; 12 month . 16 . Evaluation : History physical examination . Laboratory examination : hematology , electrolytes , chemistry . Infectious disease screen serology . HLA type . 1 . Congestive heart failure &lt; 6 month prior screen . 2 . Unstable angina pectoris &lt; 6 month prior screen . 3 . Myocardial infarction &lt; 6 month prior screen . 4 . Uncontrolled infection , define infection resolve spontaneously show evidence significant resolution initiate appropriate therapy , exclude chronic asymptomatic viral infection ( e.g. , HPV , BK virus , HCV , etc . ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Blood And Marrow Transplantation</keyword>
	<keyword>Natural killer cell</keyword>
	<keyword>NK</keyword>
	<keyword>mbIL21-expanded haploidentical NK cell</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Fludarabine monophosphate</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine arabinosine hydrochloride</keyword>
</DOC>